دورية أكاديمية
أعرض في EDS

Assessing fatty acid-induced lipotoxicity and its therapeutic potential in glioblastoma using stimulated Raman microscopy.

التفاصيل البيبلوغرافية
العنوان: Assessing fatty acid-induced lipotoxicity and its therapeutic potential in glioblastoma using stimulated Raman microscopy.
المؤلفون: Yuan Y; Department of Biomedical Engineering, Binghamton University, State University of New York, Binghamton, NY, 13902, USA., Shah N; Department of Psychology, Binghamton University, State University of New York, Binghamton, NY, 13902, USA., Almohaisin MI; Department of Biomedical Engineering, Binghamton University, State University of New York, Binghamton, NY, 13902, USA., Saha S; Department of Biomedical Engineering, Binghamton University, State University of New York, Binghamton, NY, 13902, USA., Lu F; Department of Biomedical Engineering, Binghamton University, State University of New York, Binghamton, NY, 13902, USA. fakelu@binghamton.edu.
المصدر: Scientific reports [Sci Rep] 2021 Apr 01; Vol. 11 (1), pp. 7422. Date of Electronic Publication: 2021 Apr 01.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Nonlinear Optical Microscopy*/methods, Fatty Acids/*chemistry , Fatty Acids/*pharmacology , Lipid Metabolism/*drug effects, Biomarkers ; Brain Neoplasms ; Cell Line, Tumor ; Cell Survival/drug effects ; Diacylglycerol O-Acyltransferase/metabolism ; Fatty Acids/adverse effects ; Glioblastoma ; Humans ; Image Processing, Computer-Assisted ; Lipogenesis/drug effects ; Metabolic Networks and Pathways/drug effects ; Microscopy, Fluorescence/methods ; Optical Imaging/methods
مستخلص: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. The effectiveness of traditional therapies for GBM is limited and therefore new therapies are highly desired. Previous studies show that lipid metabolism reprogramming may be a potential therapeutic target in GBM. This study aims to evaluate the therapeutic potential of free fatty acid-induced lipotoxicity for the suppression of glioma growth. U87 glioma cells are treated with three fatty acids (FAs): palmitic acid (PA), oleic acid (OA), and eicosapentaenoic acid (EPA). Uptake of the FAs and formation of lipid droplets (LDs) are imaged and quantified using a lab-built stimulated Raman scattering (SRS) microscope. Our results show that a supply of 200 µM PA, OA, and EPA leads to efficient LDs accumulation in glioma cells. We find that inhibition of triglycerides (TAGs) synthesis depletes LDs and enhances lipotoxicity, which is evidenced by the reduced cell proliferation rates. In particular, our results suggest that EPA treatment combined with depletion of LDs significantly reduces the survival rate of glioma cells by more than 50%, indicating the therapeutic potential of this approach. Future work will focus on understanding the metabolic mechanism of EPA-induced lipotoxicity to further enhance its anticancer effects.
References: Cancer Res. 2000 Nov 15;60(22):6353-8. (PMID: 11103797)
Analyst. 2019 Jan 28;144(3):753-765. (PMID: 30357117)
Prog Lipid Res. 2004 Mar;43(2):134-76. (PMID: 14654091)
Science. 2010 Jul 30;329(5991):533-8. (PMID: 20671182)
CNS Oncol. 2013 May;2(3):289-99. (PMID: 24159371)
Cell Metab. 2017 Aug 1;26(2):407-418.e3. (PMID: 28768178)
Science. 2008 Dec 19;322(5909):1857-61. (PMID: 19095943)
Stem Cells. 2014 Jul;32(7):1746-58. (PMID: 24737733)
Diabetes. 1999 Dec;48(12):2255-69. (PMID: 10580412)
Sci Rep. 2019 Dec 20;9(1):19593. (PMID: 31863022)
Anal Chem. 2017 Apr 18;89(8):4502-4507. (PMID: 28345862)
Anal Chim Acta. 2020 Jul 18;1121:57-66. (PMID: 32493590)
Science. 2010 Dec 3;330(6009):1368-70. (PMID: 21127249)
Cell Metab. 2017 Mar 7;25(3):686-697. (PMID: 28273483)
Biochim Biophys Acta. 1984 Jan 27;779(1):89-137. (PMID: 6229284)
J Biomed Opt. 2016 Jun;21(6):61003. (PMID: 26719944)
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3077-82. (PMID: 12629214)
Cell Death Differ. 2006 Jul;13(7):1238-41. (PMID: 16456578)
Front Cell Dev Biol. 2015 Aug 12;3:49. (PMID: 26322308)
Prostaglandins Leukot Essent Fatty Acids. 2010 Apr-Jun;82(4-6):149-54. (PMID: 20206486)
Oncol Rep. 2018 Jan;39(1):239-246. (PMID: 29192322)
J Biophotonics. 2017 Sep;10(9):1217-1226. (PMID: 28164480)
Sci Transl Med. 2013 Sep 4;5(201):201ra119. (PMID: 24005159)
Opt Lett. 2013 Jan 15;38(2):145-7. (PMID: 23454943)
PeerJ. 2018 Apr 26;6:e4696. (PMID: 29713567)
Cancer Res. 2016 Jun 15;76(12):3451-62. (PMID: 27197198)
J Biol Chem. 2011 Dec 2;286(48):41838-41851. (PMID: 21990351)
Intern Med Rev (Wash D C). 2017 May;3(5):. (PMID: 29034362)
Biomed Eng Online. 2003 May 17;2:13. (PMID: 12801419)
Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Jul;1863(7):783-793. (PMID: 29654826)
J Lipid Res. 2005 Jul;46(7):1502-11. (PMID: 15834126)
J Lipid Res. 2003 Jan;44(1):118-27. (PMID: 12518030)
Nat Methods. 2012 Jun 28;9(7):676-82. (PMID: 22743772)
FASEB J. 2010 Jan;24(1):296-308. (PMID: 19723703)
Clin Cancer Res. 2016 Nov 1;22(21):5337-5348. (PMID: 27281560)
Lab Invest. 2012 Mar;92(3):466-73. (PMID: 22083670)
J Phys Chem B. 2013 Apr 25;117(16):4634-40. (PMID: 23256635)
Lipids Health Dis. 2014 Sep 02;13:142. (PMID: 25182732)
Dev Cell. 2017 Jul 10;42(1):9-21.e5. (PMID: 28697336)
Int J Mol Sci. 2016 Aug 31;17(9):. (PMID: 27589734)
Sci Adv. 2018 Nov 16;4(11):eaat7715. (PMID: 30456301)
J Lipid Res. 2019 Jun;60(6):1112-1120. (PMID: 30936184)
Genes Dis. 2016 May 11;3(3):198-210. (PMID: 30258889)
Cancer Res. 2012 Feb 1;72(3):645-54. (PMID: 22139378)
Curr Opin Lipidol. 2003 Jun;14(3):281-7. (PMID: 12840659)
Curr Biol. 2013 Aug 5;23(15):1489-96. (PMID: 23871243)
Science. 2015 Nov 27;350(6264):aaa8870. (PMID: 26612955)
J Am Chem Soc. 2012 Feb 29;134(8):3623-6. (PMID: 22316340)
Neurochem Res. 2012 Jun;37(6):1192-200. (PMID: 22228201)
Prostaglandins Leukot Essent Fatty Acids. 1999 May-Jun;60(5-6):291-7. (PMID: 10471111)
Commun Biol. 2020 Jul 10;3(1):372. (PMID: 32651434)
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11624-9. (PMID: 26324899)
J Lipid Res. 2008 Nov;49(11):2283-301. (PMID: 18757836)
Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):19-29. (PMID: 12051954)
N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009)
Nat Med. 1999 Nov;5(11):1323-7. (PMID: 10546002)
معلومات مُعتمدة: R00 EB020749 United States EB NIBIB NIH HHS
المشرفين على المادة: 0 (Biomarkers)
0 (Fatty Acids)
EC 2.3.1.20 (DGAT1 protein, human)
EC 2.3.1.20 (DGAT2 protein, human)
EC 2.3.1.20 (Diacylglycerol O-Acyltransferase)
تواريخ الأحداث: Date Created: 20210402 Date Completed: 20211122 Latest Revision: 20211122
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8016949
DOI: 10.1038/s41598-021-86789-9
PMID: 33795756
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-021-86789-9